Skip to main content

auryxia

Generic: ferric citrate

auryxia: developed by 2 companies · 1 FDA decision.

auryxia evidence translation

What we can confirm

1 FDA record

What it means

More than one developer is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

What is verified about auryxia, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 0 study sponsors

Related indications

Control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD) and treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD).Treatment of iron deficiency anemia in adults with CKD, not on dialysis

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (2)
CompanyPhase
Akebia Therapeutics, Inc. (AKBA)
Control of serum phosphorus levels in adult patients with di…
Phase 3
KERYX BIOPHARMACEUTICALS INC (KERYX)
Treatment of iron deficiency anemia in adults with CKD, not …
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE Ferric citrate tablets are a phosphate binder indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis. ( 1 ) Ferric citrate tablets are an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis. ( 1 ) 1.1 Hyperphosphatemia in Chronic Kidney Disease on Dialysis Ferric citrate tablets are indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis. 1.2 Iron Deficiency Anemia in Chronic Kidney Disease Not on Dialysis Ferric citrate tablets are indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis.(KERYX)FDA ↗
NDA205874Type 5 - New Formulation or New ManufacturerStandardOralTablet

Frequently asked questions

Who is developing auryxia?

auryxia is being developed by Akebia Therapeutics, Inc., KERYX BIOPHARMACEUTICALS INC.

What is auryxia's latest FDA decision?

The most recent tracked FDA decision for auryxia is Approval for 1 INDICATIONS AND USAGE Ferric citrate tablets are a phosphate binder indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis. ( 1 ) Ferric citrate tablets are an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis. ( 1 ) 1.1 Hyperphosphatemia in Chronic Kidney Disease on Dialysis Ferric citrate tablets are indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis. 1.2 Iron Deficiency Anemia in Chronic Kidney Disease Not on Dialysis Ferric citrate tablets are indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis., dated September 5, 2014.